Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.62 |
| ▸ | HTR7 | P34969 | 6/20 | 0.57 |
| ▸ | HTR1A | P08908 | 5/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.57 |
| ▸ | HTR3B | O95264 | 4/20 | 0.57 |
| ▸ | HTR3A | P46098 | 4/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.57 |
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678428 | 1.00 | ADRB1 (0.62) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL30609613 | 0.98 | ADRB1 (0.60) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL6265761 | 0.85 | HTR7 (0.59) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL21965857 | 0.84 | ADRB1 (0.55) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL6239706 | 0.84 | FFAR4 (0.49) | ADRB1HTR7HTR1AHTR2CHTR6 | |
| SCHEMBL27613691 | 0.82 | PRMT6 (0.50) | HTR7HTR1AHTR2CHTR6HTR2A | |
| SCHEMBL1111778 | 0.82 | PHGDH (0.48) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL27858925 | 0.81 | PRMT6 (0.49) | THRBTP53HTTDDB1CRBN | |
| SCHEMBL14303298 | 0.80 | HTR3A (0.63) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL23411314 | 0.79 | CYP2D6 (0.54) | ADRB1HTR7HTR1AHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1433407-A | Bis-aryl sulfones | PHARMACIA & UP JOHN CO (US) | 2003-07-30 | — | — | CN | claimed |
| EP-3708169-A1 | 2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | Agios Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| EP-2279174-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-7491727-B2 | Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches | EPIX DELAWARE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491727-B2 | Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches | EPIX DELAWARE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491727-B2 | Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches | EPIX DELAWARE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7488731-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488731-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| CN-1756551-A | New arylpiperazinyl compounds | PREDIX PHARMACEUTICALS HOLDING (US) | 2006-04-05 | — | — | CN | disclosed |
| EP-1592425-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | Predix Pharmaceuticals Holdings, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1590329-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2005-11-02 | — | — | EP | disclosed |
| CN-1217938-C | Bis-arylsulfones | PHARMACIA & UP JOHN CO (US) | 2005-09-07 | — | — | CN | disclosed |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-06-16 | — | — | US | disclosed |
| WO-2004069794-A9 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDING (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040220192-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004078732-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004069794-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| CN-1433407-A | Bis-aryl sulfones | PHARMACIA & UP JOHN CO (US) | 2003-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AHR, NQO1, ARNT | ADRB1 2203/4885HTR7 1802/4885HTR1A 2645/4885 |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | ADRB1 4707/4885HTR7 2134/4885HTR1A 3852/4885 |
| US-20040220192-A1 | Arylpiperazinyl compounds | HTR5A, HTR1A, HTR2A | ADRB1 28/4885HTR7 7/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.